Evogene Ltd
Evogene Ltd (EVGN) is an Israel-based computational biology company developing crop traits, biologicals and precision ag solutions using proprietary algorithms and genomics platforms. It licences technology to partners and advances a pipeline of trait candidates and biological products aimed at improving yield, stress tolerance and pest resistance. For investors, key points are Evogene’s technology-driven model, reliance on partnerships and R&D milestones, and the typical long timelines of agricultural biotech development. The company’s small market capitalisation suggests higher volatility and potential liquidity constraints; results from trials, partner deals or regulatory steps can markedly move the share price. Financial strength, cash burn and the success of collaborations are material considerations. This summary provides general, educational information — not personalised investment advice — and investors should be aware that returns are not guaranteed and company prospects can decline as well as improve.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Evogene's stock as it has significant potential for price increase.
Financial Health
Evogene Ltd has steady revenue and gross margins, but cash flow indicates some financial challenges.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring EVGN
Synthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Computational Biology Edge
Evogene’s algorithms aim to speed discovery of crop traits and biologicals, which may reduce time to candidate identification — though laboratory and field validation remain uncertain.
Partnerships Drive Commercialisation
The company often licences technology to larger agricultural firms to scale products, so partnership deals and collaborations materially affect future revenue prospects.
Micro‑cap Risk Profile
With a market cap near $11m, shares can be volatile and liquidity limited; financial runway and funding needs are important considerations for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
